Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012833 (
dizziness
)
9,689
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear protein in testis (NUT) midline carcinoma is poorly differentiated carcinoma defined by rearrangement of NUT gene on 15 to other genes, usually
BRD4
on 19. It is first described in 1991. These tumors are most commonly seen in the mediastinum and 35% occur in head and neck. It is a highly aggressive tumor with a median survival of 7 months because of ineffective chemotherapy and undefined treatment. Hence, we must differentiate these tumors from other poorly differentiated tumors. Here, we present a case of NUT midline carcinoma of 44-year male, who presented with headache and
dizziness
, confirmed by immunohistochemistry of NUT antibody. The aim of this case report is to increase the awareness about this entity in adults with brief review of relevant literature.
...
PMID:Sinonasal NUT midline carcinoma: A new histological entity. 3203 Nov 34
As epigenetic readers of the histone code,
BRD4
is the most extensively and thoroughly studied member of BET family, which plays a critical role in many human diseases including cancer, inflammation, HIV infections, CNS disorders, and cardiovascular diseases and has been proved to be a promising therapeutic target for these diseases. To date, many small-molecule
BRD4
inhibitors have been discovered, and some of them are in clinical trials for the treatment of different diseases. Due to the lack of selectivity of these small molecules for
BRD4
BD1,
BRD4
BD2 and/or other BET proteins, they exert some toxic side effects, including
dizziness
, nausea, and vomit. Now, novel strategies are urgent needed to improve the selectivity and reduce the side effects of current
BRD4
inhibitors. Herein, in this article, we made a summary of the recent development of novel strategies targeting
BRD4
. Opportunities for these strategies to achieve selective and efficacious
BRD4
inhibitors for treating human diseases are also highlighted.
...
PMID:Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. 3250 63